{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sahpra-submissions-and-ec-approvals-coordination”
},
“@id”: “https://www.clinicalstudies.in/sahpra-submissions-and-ec-approvals-coordination”,
“headline”: “SOP for SAHPRA Submissions and EC Approvals Coordination”,
“name”: “SOP for SAHPRA Submissions and EC Approvals Coordination”,
“description”: “Comprehensive SOP for sponsors, investigators, and regulatory staff managing submissions to SAHPRA and coordinating with Ethics Committees (ECs) in South Africa, ensuring timely approvals and compliance.”,
“keywords”: “SAHPRA submission SOP, SAHPRA clinical trial approval, South Africa clinical trial SOP, SOP for SAHPRA EC coordination, SAHPRA ethics approval SOP, SOP for dual submission SAHPRA EC, SOP for investigator site submission South Africa, SOP for sponsor obligations SAHPRA, clinical trial governance South Africa SOP, SAHPRA clinical trial licensing, SOP for EC approval South Africa, SOP for protocol submission SAHPRA, SOP for site-specific assessment South Africa, SOP for investigator responsibility SAHPRA, SOP for trial lifecycle South Africa, SOP for inspection readiness SAHPRA, SOP for clinical trial coordination SAHPRA, SOP for site initiation South Africa, SOP for regulatory document submission SAHPRA, SOP for sponsor-SAHPRA interaction, SOP for EC queries South Africa, SOP for submission tracker SAHPRA, SOP for amendment submissions SAHPRA, SOP for sponsor compliance South Africa, SOP for TMF documentation SAHPRA”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

SAHPRA Submissions and EC Approvals Coordination SOP

Purpose

The purpose of this SOP is to define standardized procedures for preparing and submitting clinical trial applications to the South African Health Products Regulatory Authority (SAHPRA) and coordinating with local Ethics Committees (ECs). It ensures compliance with South African regulations, Good Clinical Practice (GCP), and international standards for ethical trial conduct.

Scope

This SOP applies to all clinical trials conducted in South Africa that require approval from SAHPRA and local ECs. It includes submission of Clinical Trial Applications (CTAs), essential documents, safety reports, amendments, and coordination of dual approvals prior to site initiation. It applies to sponsors, CROs, investigators, and regulatory affairs teams.

Responsibilities

• Sponsor: Prepares the CTA and ensures both SAHPRA and EC approvals are obtained before trial initiation.
• Regulatory Affairs (RA): Manages dossier preparation, submission, and communication with SAHPRA and ECs.
• Principal Investigator (PI): Provides site-specific documents and ensures site initiation only after approvals.
• Clinical Project Manager (CPM): Tracks timelines, monitors submissions, and records approvals in TMF.
• Quality Assurance (QA): Audits submission packages and ensures readiness for SAHPRA inspections.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for ensuring submissions to SAHPRA and ECs meet requirements. The PI is accountable for ensuring trial conduct does not commence without both approvals.

Procedure

1. Preparation of Clinical Trial Application (CTA)

1. Compile CTA package including protocol, Investigator’s Brochure, informed consent forms, investigational product information, GMP certificates, and insurance certificates.
2. Ensure dossier follows SAHPRA’s guidance on electronic submission format.
3. Maintain CTA Preparation Checklist in TMF (Annexure-1).

2. Submission to SAHPRA

1. Submit CTA electronically through SAHPRA Clinical Trials portal.
2. Record acknowledgement reference number and submission date in Submission Log.
3. Respond to SAHPRA queries within stipulated timelines.

3. Ethics Committee (EC) Submissions

1. Prepare ethics submission package including protocol, informed consent forms, recruitment materials, and PI CVs.
2. Submit package to EC simultaneously with SAHPRA submission.
3. Document EC approval letters and file in TMF and ISF.

4. Coordination of Approvals

1. Ensure no site initiations occur until both SAHPRA and EC approvals are obtained.
2. Record final approvals in Approval Tracker (Annexure-2).

5. Amendments

1. Classify amendments as substantial or administrative.
2. Submit substantial amendments to both SAHPRA and EC before implementation.
3. Maintain Amendment Log (Annexure-3).

6. Safety Reporting

1. Submit SUSARs, DSURs, and safety notifications to SAHPRA and EC per timelines.
2. Ensure acknowledgment receipts are filed.

7. Archiving

1. Archive submission packages, approval letters, and correspondence for 15 years or as per SAHPRA requirements.

Abbreviations

• SAHPRA: South African Health Products Regulatory Authority
• EC: Ethics Committee
• CTA: Clinical Trial Application
• PI: Principal Investigator
• RA: Regulatory Affairs
• QA: Quality Assurance
• CPM: Clinical Project Manager
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. CTA Preparation Checklist (Annexure-1)
2. Approval Tracker (Annexure-2)
3. Amendment Log (Annexure-3)

References

• SAHPRA — Clinical Trials
• ICH E6(R2) Good Clinical Practice
• ICH Efficacy Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: CTA Preparation Checklist

Annexure-2: Approval Tracker

Annexure-3: Amendment Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/community-engagement-in-hiv-tb-and-vulnerable-groups”
},
“@id”: “https://www.clinicalstudies.in/community-engagement-in-hiv-tb-and-vulnerable-groups”,
“headline”: “SOP for Community Engagement in HIV, TB and Vulnerable Groups”,
“name”: “SOP for Community Engagement in HIV, TB and Vulnerable Groups”,
“description”: “Detailed SOP describing sponsor, investigator, and site responsibilities for community engagement in HIV, TB, and vulnerable group clinical trials conducted in South Africa to ensure ethical compliance and participant protection.”,
“keywords”: “community engagement SOP South Africa, SOP for HIV trial community engagement, SOP for TB trial participant engagement, SOP for vulnerable population engagement, SAHPRA ethics requirements community, SOP for informed consent support South Africa, SOP for trial outreach programs, SOP for stakeholder engagement clinical trials, SOP for cultural considerations HIV TB trials, SOP for ethics in vulnerable group trials, SOP for trial awareness South Africa, SOP for sponsor community engagement, SOP for CRO engagement responsibilities, SOP for patient advocacy involvement, SOP for site engagement activities South Africa, SOP for investigator community responsibilities, SOP for recruitment in vulnerable groups South Africa, SOP for EC community approval South Africa, SOP for engagement documentation SOP, SOP for ethics monitoring community trials, SOP for capacity building HIV TB trials, SOP for compliance inspection readiness South Africa, SOP for communication with local communities, SOP for subject protection vulnerable populations, SOP for trial governance community engagement”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Community Engagement in HIV, TB and Vulnerable Groups SOP

Purpose

This SOP defines procedures for community engagement in clinical trials involving HIV, TB, and vulnerable populations in South Africa. It ensures participants are informed, culturally respected, and ethically protected, in line with SAHPRA, Ethics Committee (EC), and Good Clinical Practice (GCP) requirements.

Scope

This SOP applies to all sponsor-led and investigator-initiated trials in South Africa that involve vulnerable populations, including people living with HIV, TB patients, and socioeconomically disadvantaged communities. It covers engagement planning, outreach, ethics review, community advisory board (CAB) interactions, and ongoing monitoring.

Responsibilities

• Sponsor: Ensures community engagement strategies are developed and approved before trial initiation.
• Principal Investigator (PI): Implements site-level engagement and maintains communication with local communities.
• Community Advisory Board (CAB): Provides input on cultural sensitivity and trial acceptability.
• Clinical Research Coordinator (CRC): Facilitates community education sessions and maintains engagement logs.
• Regulatory Affairs (RA): Submits engagement plans to EC for approval.
• Quality Assurance (QA): Audits community engagement activities for compliance.

Accountability

The Sponsor’s Head of Clinical Operations is accountable for ensuring community engagement strategies are aligned with regulatory expectations. The PI is accountable for ensuring ongoing communication with trial participants and vulnerable groups.

Procedure

1. Development of Community Engagement Plan

1. Draft a Community Engagement Plan outlining objectives, stakeholders, and methods of engagement.
2. Submit the plan to EC for approval before trial initiation.
3. Maintain plan in TMF and update as required.

2. Formation of Community Advisory Board (CAB)

1. Identify and recruit members from local communities, advocacy groups, and healthcare representatives.
2. Define CAB terms of reference and meeting schedules.

3. Community Outreach Activities

1. Conduct pre-trial sensitization workshops in local languages.
2. Provide culturally appropriate educational materials.
3. Document community questions and feedback in Outreach Log.

4. Ongoing Engagement During Trial

1. Hold quarterly CAB meetings to discuss trial progress and concerns.
2. Maintain transparent communication with participants regarding safety updates and trial outcomes.

5. Ethics Oversight

1. Submit records of community engagement activities to ECs periodically.
2. Address EC feedback and update engagement strategies as required.

6. Documentation and Archiving

1. Maintain Engagement Logs, CAB meeting minutes, and Outreach Logs in TMF and ISF.
2. Archive engagement records for at least 15 years or per SAHPRA requirements.

Abbreviations

• SAHPRA: South African Health Products Regulatory Authority
• EC: Ethics Committee
• CAB: Community Advisory Board
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• RA: Regulatory Affairs
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Community Engagement Plan (Annexure-1)
2. Outreach Log (Annexure-2)
3. CAB Meeting Minutes (Annexure-3)

References

• SAHPRA — Clinical Trials
• ICH E6(R2) Good Clinical Practice
• Office for Human Research Protections (OHRP)

Version: 1.0

Approval

Annexures

Annexure-1: Community Engagement Plan

Annexure-2: Outreach Log

Annexure-3: CAB Meeting Minutes

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/local-import-and-export-permits-for-investigational-products-and-samples”
},
“@id”: “https://www.clinicalstudies.in/local-import-and-export-permits-for-investigational-products-and-samples”,
“headline”: “SOP for Local Import and Export Permits for Investigational Products and Samples”,
“name”: “SOP for Local Import and Export Permits for Investigational Products and Samples”,
“description”: “Detailed SOP describing the responsibilities of sponsors, investigators, and regulatory staff in obtaining, maintaining, and managing local import and export permits for investigational products (IP) and biological samples in South Africa, ensuring compliance with SAHPRA requirements.”,
“keywords”: “import export permits SOP South Africa, SAHPRA import license clinical trials, SOP for IP import South Africa, SOP for biological sample export South Africa, customs clearance SOP SAHPRA, SOP for trial material shipping South Africa, regulatory compliance import export SOP, SOP for SAHPRA customs approval, SOP for sponsor obligations import permits, site-level responsibilities import South Africa, SOP for clinical trial supply chain South Africa, investigational product licensing SAHPRA, SOP for documentation import permits, SOP for biological sample governance, SOP for CRO logistics support South Africa, SOP for inspection readiness import SAHPRA, SOP for permit renewal clinical trials, SOP for SAHPRA investigator site supply, SOP for regulatory submissions customs South Africa, SOP for IP shipment documentation, SOP for sponsor compliance import export, SOP for shipping tracker South Africa, SOP for archival of import permits, SOP for customs interaction SOP South Africa, SOP for clinical trial governance import export”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Local Import and Export Permits for Investigational Products and Samples SOP

Purpose

This SOP defines the process for obtaining, managing, and maintaining local import and export permits for investigational products (IPs) and biological samples in South Africa. It ensures compliance with SAHPRA regulations, customs requirements, and international GCP standards to safeguard clinical trial supply chain integrity.

Scope

This SOP applies to all sponsor-led clinical trials in South Africa requiring importation of investigational medicinal products (IMPs), comparators, placebos, and export of biological samples for analysis. It covers permit applications, renewals, customs clearance, CRO/vendor roles, and document archiving. It applies to sponsors, CROs, investigators, and regulatory affairs teams.

Responsibilities

• Sponsor: Ensures all IP shipments and biological sample exports have valid permits before transportation.
• Regulatory Affairs (RA): Prepares and submits applications to SAHPRA and Department of Agriculture, Forestry and Fisheries (DAFF) if applicable.
• Logistics Manager: Oversees customs clearance and shipment documentation, ensuring compliance with approved permits.
• Principal Investigator (PI): Confirms receipt of imported IPs and ensures site-level documentation is maintained.
• Quality Assurance (QA): Verifies that all permits and shipment logs are complete and inspection-ready.
• CRO: Provides support in coordinating logistics, customs, and document filings when delegated.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for ensuring all permits are valid and compliant with South African regulations. The PI is accountable for maintaining records of IPs and biological sample movement at the site level.

Procedure

1. Pre-Application Assessment

1. Determine whether the shipment requires an import or export permit under SAHPRA guidelines.
2. Document details in Import/Export Requirement Form (Annexure-1).

2. Permit Application

1. Prepare dossier including protocol, product details, MSDS, GMP certificate, and justification.
2. Submit permit application to SAHPRA electronically.
3. Record submission reference number in Permit Application Log.

3. Customs Clearance

1. Ensure shipments align with approved permits, including labeling and documentation.
2. Maintain Shipping Tracker capturing customs clearance details.

4. Renewal and Amendments

1. Initiate renewal process 60 days prior to permit expiration.
2. Submit updated protocol or supply details for significant amendments.

5. Documentation and Archiving

1. File permits, clearance receipts, and shipping records in TMF.
2. Archive documents for 15 years or per SAHPRA guidance.

Abbreviations

• SAHPRA: South African Health Products Regulatory Authority
• IP: Investigational Product
• IMP: Investigational Medicinal Product
• MSDS: Material Safety Data Sheet
• PI: Principal Investigator
• RA: Regulatory Affairs
• QA: Quality Assurance
• CRO: Contract Research Organization
• TMF: Trial Master File

Documents

1. Import/Export Requirement Form (Annexure-1)
2. Permit Application Log (Annexure-2)
3. Shipping Tracker (Annexure-3)

References

• SAHPRA — Clinical Trials
• ICH E6(R2) Good Clinical Practice
• WHO Clinical Trials Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: Import/Export Requirement Form

Annexure-2: Permit Application Log

Annexure-3: Shipping Tracker

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/local-pharmacovigilance-and-icsr-submission-pathways”
},
“@id”: “https://www.clinicalstudies.in/local-pharmacovigilance-and-icsr-submission-pathways”,
“headline”: “SOP for Local Pharmacovigilance and ICSR Submission Pathways”,
“name”: “SOP for Local Pharmacovigilance and ICSR Submission Pathways”,
“description”: “Detailed SOP defining sponsor, investigator, and CRO responsibilities for local pharmacovigilance reporting and ICSR submissions in South Africa, ensuring compliance with SAHPRA and ICH GCP requirements.”,
“keywords”: “local PV reporting SOP South Africa, SAHPRA pharmacovigilance SOP, SOP for ICSR submissions South Africa, adverse event reporting SAHPRA, SOP for SUSAR reporting South Africa, PV compliance SOP South Africa, SOP for DSUR submission South Africa, SOP for investigator SAE reporting South Africa, clinical trial safety SOP South Africa, SOP for sponsor PV obligations South Africa, SOP for CRO pharmacovigilance management, SOP for PV inspection readiness SAHPRA, SOP for regulatory timelines South Africa, SOP for SAE case reporting South Africa, SOP for safety database SAHPRA compliance, SOP for expedited reporting South Africa, SOP for trial safety governance South Africa, SOP for regulatory safety submission logs, SOP for ICSR quality management, SOP for PV audit compliance South Africa, SOP for adverse drug reaction reporting SAHPRA, SOP for site safety obligations South Africa, SOP for PV training requirements South Africa, SOP for safety record archiving South Africa, SOP for sponsor QA PV South Africa”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Local Pharmacovigilance and ICSR Submission Pathways SOP

Purpose

The purpose of this SOP is to establish procedures for local pharmacovigilance (PV) reporting and Individual Case Safety Report (ICSR) submissions in South Africa. It ensures compliance with SAHPRA requirements for safety reporting in clinical trials, safeguarding subject safety and maintaining trial integrity.

Scope

This SOP applies to all sponsor-led and investigator-initiated clinical trials conducted in South Africa. It covers SAE identification, SUSAR reporting, ICSR submission timelines, DSUR submissions, safety narrative preparation, and archiving. It applies to sponsors, investigators, CROs, regulatory affairs, and PV teams.

Responsibilities

• Principal Investigator (PI): Identifies and reports SAEs to the sponsor within 24 hours, completes SAE forms, and ensures timely documentation in the ISF.
• Clinical Research Coordinator (CRC): Assists PI in reporting and filing safety documents.
• Pharmacovigilance (PV) Team: Conducts medical assessment, prepares narratives, and ensures ICSRs are submitted to SAHPRA per timelines.
• Regulatory Affairs (RA): Confirms acknowledgments from SAHPRA and ensures DSUR submissions.
• Quality Assurance (QA): Reviews safety reporting systems, ensuring compliance with inspection readiness standards.
• CRO (if applicable): Supports PV case management and submission activities.

Accountability

The Sponsor’s Qualified Person for Pharmacovigilance (QPPV) or equivalent in South Africa is accountable for ensuring compliance with safety reporting obligations. The PI is accountable for initial SAE detection and prompt reporting.

Procedure

1. SAE Identification and Initial Reporting

1. Document all SAEs in SAE forms within 24 hours of awareness.
2. Forward SAE reports to sponsor for causality and expectedness assessment.
3. File copies of SAE reports in the ISF.

2. ICSR Submission Timelines

1. Fatal or life-threatening SUSARs: submit to SAHPRA within 7 calendar days with follow-up within 8 days.
2. Other SUSARs: submit within 15 calendar days.
3. Non-serious ICSRs: submit as periodic line listings as per SAHPRA guidance.

3. Data Entry and Submission

1. PV team enters ICSRs into SAHPRA’s electronic reporting system.
2. Ensure narratives, laboratory data, and outcomes are included.
3. Retain acknowledgment receipts in the TMF.

4. Development Safety Update Reports (DSURs)

1. Prepare DSUR annually including cumulative safety data.
2. Submit DSUR to SAHPRA within 60 days of the data lock point.

5. Training

1. Ensure all staff involved in PV reporting are trained on SAE reporting timelines and SAHPRA electronic systems.
2. Maintain training logs in TMF.

6. Archiving

1. Archive SAE reports, SUSAR logs, ICSRs, DSURs, and acknowledgment receipts for 15 years or per SAHPRA requirements.

Abbreviations

• SAHPRA: South African Health Products Regulatory Authority
• PV: Pharmacovigilance
• ICSR: Individual Case Safety Report
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR: Development Safety Update Report
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• RA: Regulatory Affairs
• QA: Quality Assurance
• QPPV: Qualified Person for Pharmacovigilance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. SAE Form (Annexure-1)
2. ICSR Submission Log (Annexure-2)
3. DSUR Tracker (Annexure-3)

References

• SAHPRA — Clinical Trials and Pharmacovigilance
• ICH E6(R2) Good Clinical Practice
• ICH E2A: Clinical Safety Data Management
• ICH E2F: Development Safety Update Report

Version: 1.0

Approval

Annexures

Annexure-1: SAE Form

Annexure-2: ICSR Submission Log

Annexure-3: DSUR Tracker

Revision History

For more SOPs visit: Pharma SOP.